GD 11
Alternative Names: GD-11Latest Information Update: 24 Mar 2024
Price :
$50 *
At a glance
- Originator Jiangsu Wangao Pharmaceutical
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Stroke
Most Recent Events
- 29 Feb 2024 Phase-III clinical trials in Stroke in China (IV) (NCT06299579)
- 17 Nov 2022 Phase-II clinical trials in Stroke in China (IV) (CTR20222803)